BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 21984449)

  • 21. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
    Giovagnoni A; Paci E
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
    Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
    Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hepatobiliary uptake of Gd-EOB-DTPA on the hepatic venous phase of dynamic magnetic resonance imaging on a 3.0-T apparatus: comparison between Gd-EOB-DTPA and Gd-DTPA.
    Fujinaga Y; Ohya A; Matsushita T; Kurozumi M; Ueda K; Kitou Y; Ueda H; Kadoya M
    Jpn J Radiol; 2011 Dec; 29(10):695-700. PubMed ID: 22009420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of models and contrast agents for improved signal and signal linearity in dynamic contrast-enhanced pulmonary magnetic resonance imaging.
    Bell LC; Wang K; Munoz Del Rio A; Grist TM; Fain SB; Nagle SK
    Invest Radiol; 2015 Mar; 50(3):174-8. PubMed ID: 25501016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation.
    Okamoto D; Nishie A; Asayama Y; Tajima T; Ishigami K; Kakihara D; Nakayama T; Ohga S; Yoshitake T; Shioyama Y; Honda H
    Magn Reson Imaging; 2014 Jul; 32(6):660-4. PubMed ID: 24666574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes.
    Daire JL; Leporq B; Vilgrain V; Van Beers BE; Schmidt S; Pastor CM
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):657-667. PubMed ID: 27778300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.
    Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL
    Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partition coefficients for gadolinium chelates in the normal myocardium: comparison of gadopentetate dimeglumine and gadobenate dimeglumine.
    Kawel N; Nacif M; Santini F; Liu S; Bremerich J; Arai AE; Bluemke DA
    J Magn Reson Imaging; 2012 Sep; 36(3):733-7. PubMed ID: 22488770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gd-BOPTA transport into rat hepatocytes: pharmacokinetic analysis of dynamic magnetic resonance images using a hollow-fiber bioreactor.
    Planchamp C; Gex-Fabry M; Dornier C; Quadri R; Reist M; Ivancevic MK; Vallée JP; Pochon S; Terrier F; Balant L; Stieger B; Meier PJ; Pastor CM
    Invest Radiol; 2004 Aug; 39(8):506-15. PubMed ID: 15257212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies.
    Powerski MJ; Scheurig-Münkler C; Hamm B; Gebauer B
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):472-80. PubMed ID: 24964737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of using half-dose Gd-BOPTA for delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at the knee, compared with standard-dose Gd-DTPA.
    Rehnitz C; Do T; Klaan B; Burkholder I; Barié A; Wuennemann F; Kauczor HU; Weber MA
    J Magn Reson Imaging; 2020 Jan; 51(1):144-154. PubMed ID: 31141254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models.
    Jaw TS; Chen SH; Wang YM; Hsu JS; Kuo YT; Chiu YY; Tsai KB; Hsieh TJ; Liu GC
    Kaohsiung J Med Sci; 2012 Mar; 28(3):130-7. PubMed ID: 22385605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of gadobenate dimeglumine and gadopentetate dimeglumine: a study of MR imaging and inductively coupled plasma atomic emission spectroscopy in rat brain tumors.
    Zhang T; Matsumura A; Yamamoto T; Yoshida F; Nose T; Shimojo N
    AJNR Am J Neuroradiol; 2002 Jan; 23(1):15-8. PubMed ID: 11827870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
    Zhang HM; Ouyang H; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
    Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
    Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate.
    Schmid-Tannwald C; Herrmann K; Oto A; Panteleon A; Reiser M; Zech C
    Acta Radiol; 2012 Nov; 53(9):961-5. PubMed ID: 23024179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gd-EOB-DTPA enhanced MRI of the liver: correlation of relative hepatic enhancement, relative renal enhancement, and liver to kidneys enhancement ratio with serum hepatic enzyme levels and eGFR.
    Talakic E; Steiner J; Kalmar P; Lutfi A; Quehenberger F; Reiter U; Fuchsjäger M; Schöllnast H
    Eur J Radiol; 2014 Apr; 83(4):607-11. PubMed ID: 24380639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
    Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
    Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.